Medicilon(SH:688202) Shang Hai Zheng Quan Bao·2025-11-19 18:04Core Viewpoint - The announcement details a share reduction plan by shareholder Chen Guoxing of Shanghai Medicy Bio-Pharmaceutical Co., Ltd., indicating a planned reduction of up to 2,200,000 shares, which is 1.64% of the total share capital, due to personal funding needs [3][11]. Shareholder Holdings - As of the announcement date, shareholder Chen Guoxing holds 4,875,154 shares, representing 3.63% of the total share capital, while together with his concert party Lin Changqing, they hold a total of 8,806,324 shares, accounting for 6.55% of the total share capital [2]. Reduction Plan Details - The reduction will be executed through centralized bidding and block trading within three months after the disclosure of the reduction plan, excluding periods when reductions are prohibited by regulations [3][6]. - The reduction price will be determined based on market prices at the time of the reduction, and adjustments will be made if there are changes in share capital due to dividends, stock splits, or other corporate actions [3][11]. Future Holding Intentions - After the completion of the reduction plan, Chen Guoxing intends to continue holding shares in the company and will comply with relevant laws and regulations regarding further reductions based on personal development needs [3][8]. Previous Commitments - Chen Guoxing has made commitments regarding shareholding, including a lock-up period of 36 months post-IPO, restrictions on transferring shares during certain conditions, and a maximum of 25% transfer of shares per year while serving as a director or senior management [7][8].